recombin
mersn
produc
cell
describ
previous
mersn
elisa
also
perform
previous
describ
western
blot
analysi
purifi
n
pet
control
lysat
purifi
run
sd
page
transfer
pvdf
membran
sera
without
mercov
reactiv
nh
sar
merscov
dilut
use
probe
blot
hrp
goat
anti
human
iga
igg
igm
h
l
blot
develop
dab
receiveroper
characterist
roc
analysi
use
determin
diagnost
sensit
specif
optim
test
cutoff
od
valu
assay
use
excel
ibm
spss
statist
softwar
briefli
diagnost
sensit
se
specif
sp
elisa
test
result
calcul
use
microneutr
result
refer
gold
standard
test
merscov
posit
neg
sampl
optim
test
cutoff
od
valu
ascertain
plot
sensit
se
specif
sp
elisa
cutoff
od
valu
two
graphroc
plot
intersect
two
curv
determin
cutoff
od
elisa
use
commerci
prepar
purifi
ectodomain
merscov
optim
coat
block
condit
indirect
elisa
use
known
merscov
neg
posit
human
sera
data
shown
optim
test
sera
normal
human
donor
figur
use
od
cutoff
one
normal
human
sera
cutoff
order
precis
test
specif
sensit
elisa
nine
true
neg
sera
reciproc
endpoint
microneutr
titer
less
nine
true
posit
sera
reciproc
endpoint
microneutr
titer
rang
test
dilut
figur
roc
analysi
perform
calcul
diagnost
sensit
true
posit
specif
true
neg
assay
standard
screen
dilut
sensit
elisa
remain
greater
od
figur
specif
increas
od
figur
serum
dilut
elisa
remain
highli
specif
lose
sensit
higher
od
expect
figur
n
lower
od
elisa
specif
n
elisa
retain
higher
sensit
across
larg
rang
od
data
consist
one
public
examin
serial
blood
draw
singl
merscov
patient
suggest
elisa
sensit
n
elisa
observ
signific
patienttopati
differ
qualiti
quantiti
polyclon
antibodi
respons
conflict
data
may
simpli
explain
human
variat
immun
respons
suggest
elisa
sensit
increas
lower
breakpoint
merscov
elisa
would
captur
larger
percentag
patient
seroconvert
seen
sever
patient
never
develop
detect
merscov
antibodi
develop
n
antibodi
data
shown
second
reason
retain
n
elisa
evid
antibodi
coronaviru
n
protein
detect
earlier
infect
protein
specif
sarscov
infect
studi
indic
antibodi
n
protein
appear
antibodi
protein
frequent
receiv
serum
patient
acut
ill
suspect
mer
third
n
elisa
may
sensit
examin
n
cross
reactiv
suggest
antibodi
direct
n
may
cross
react
withingroup
coronavirus
therefor
use
n
elisa
may
captur
sensit
specif
inform
part
screen
process
aim
captur
mani
potenti
posit
serum
possibl
perform
confirmatori
assay
summari
new
test
algorithm
n
elisa
use
screen
assay
sera
dilut
sera
od
assay
cutoff
dilut
serial
fourfold
use
endpoint
titer
determin
sera
posit
either
n
n
titer
test
via
microneutr
live
merscov
along
neg
sera
defin
posit
merscov
serolog
posit
two
three
assay
test
n
elisa
elisa
microneutr
posit
microneutr
alon
microneutr
activ
confirm
posit
find
conclus
report
author
necessarili
repres
view
center
diseas
control
preventionth
nation
center
immun
